Elephant Gate Launches Acceleration Program to Back Infrastructure Builders in the Psychedelics Ecosystem

Elephant Gate will invest $150,000 in up to 10 pre-seed and seed-stage companies annually.

Elephant Gate, a new acceleration program by Pink Elephant dedicated to the psychedelics ecosystem, today announces the launch of its first cohort, with applications open through May 15, 2026. The program deploys $150,000 into up to ten pre-seed and seed-stage companies, backing founders building scalable infrastructure for the emerging psychedelics space.

Elephant Gate is building the infrastructure and guardrails for an ecosystem on the cusp of a new wave. With FDA trials scaling, state decriminalization accelerating, and new molecules approaching approval, the foundational infrastructure layer remains largely unbuilt.

The program runs from 2026 through 2028, targeting 30 portfolio companies in total across three annual cohorts. A strategic reserve is maintained for larger co-investment opportunities alongside institutional investors and drug development partnerships. While based in San Francisco, the program is global in reach and fully remote, welcoming businesses from Europe, Asia and across the world, not just those based in the United States.

The initiative has attracted a wide range of partners, including Psychedelics Today and JLS Fund. Psychedelics Today, founded in 2015, is the world's largest psychedelic media and education platform, reaching over 2.2 million annual learners through its publications, podcast, and educational programmes. JLS Fund is a venture capital fund founded in 2019, focused on neuroscience, mental health, and the infrastructure enabling psychedelic medicine, with a portfolio of investments spanning pre-seed through Series A. 

Elephant Gate backs founders building scalable infrastructure for the psychedelics ecosystem. Current areas of focus include: Education & Training, Clinical Support SaaS, AI-Supported Integration Therapy, Clinical Infrastructure & Delivery, Marketing & Patient Acquisition. The thesis is deliberately adaptive, and founders building beyond these categories are encouraged to apply.

Founders receive $150,000 in capital at pre-seed or seed terms, along with access to a network of practitioners and operators. They also receive go-to-market support and business development introductions, and a co-investment pipeline with institutional funds. Above all, founders gain a community that builds alongside them, people who are on the same journey, who understand the challenges firsthand and show up every step of the way.

“The psychedelic ecosystem is emerging from the ground up. We are here to back the entrepreneurs who are building the infrastructure that will define how millions of people access these therapeutic modalities over the next decades.”
— Natalia Fedulova, Partner at Elephant Gate

Applications for the first cohort are open through May 15, 2026. The program is open to pre-seed and seed-stage companies globally. Founders are invited to apply or reach out directly at hello@elephantgate.co. 

About Elephant Gate by Pink Elephant

Elephant Gate is an acceleration program investing in the infrastructure and guardrails of the emerging psychedelics ecosystem. The program invests $150,000 into up to ten pre-seed and seed-stage companies per year across a three-year cycle (2026–2028), targeting 30 portfolio companies in total.

Media Contact

Elephant Gate by Pink Elephant
hello@elephantgate.co